Innovation Pharmaceuticals Inc (IPIX)

[ICEVRE3]

My 2 cents regarding PK data:

Leo says "We are anticipating the tests to be run in mid-March and the results to follow shortly thereafter.

Nowhere does he mention, "and shareholders will be updated immediately."

3/14- http://seekingalpha.com/article/1273221-an-interview-with-leo-ehrlich-cellceutix-ceo

We know they are presenting at this years ASCO, and updates to abstracts are due by 4/11, this Thursday. With cohort 3 wrapping up, I'm sure they are rushing to collect and analyze the data for an updated abstract.

Leo says, "The ASCO meeting gives Cellceutix an opportunity to provide a comprehensive update on the latest data from the Kevetrin clinical trials to shareholders and leaders in the scientific community as well as time for interaction with others about possible future collaborations and studies. Furthermore, it showcases Cellceutix’s novel drug and accomplishments to many of the organizations that were first introduced to Kevetrin three years ago when it was recognized at the American Association for Cancer Research as a drug on the ‘frontier’ of cancer research.

Dr. Krishna Menon, Chief Scientific Officer at Cellceutix, commented, “We are still at the early stages of the clinical trial. To date, we have not observed any dose limiting toxicities. Initial pharmacokinetic (PK) data from the clinical trial has been received and is consistent with the animal data, which is a very optimistic sign moving forward. Additional information on these PK studies will be forthcoming at ASCO. We are now looking forward to receiving data from the p21 biomarker studies which is expected in March 2013.”

http://cellceutix.com/cellceutix-abstract-for-annual-american-society-of-clinical-oncology-meeting/

I'm looking forward to:

1. Announcement of the completion of 3rd cohort with no DLT and the start of 4th.

2. Abstracts released on ASCO.org 5/15

3. SW Cancer center PR

"Additional updates on the planned studies testing Kevetrin against Acute Myelogenous Leukemia at the University of Bologna as well as other corporate developments relating to research on Kevetrin at a world-renowned cancer center in the Southwest United States are forthcoming shortly.

4. Start of quick Phase 3 for Prurisol in the next 2 month time-frame. "Upcoming clinical trials in Europe planned for the second quarter of 2013."

-2/25 http://cellceutix.com/cellceutix-reports-on-kevetrin-clinical-trials-and-prurisol-manufacturing/

5. ASCO presentation and comprehensive shareholder update regarding PK and DLT data for Kevetrin.